Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179082 | 0.88 | HPGD (0.73) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3559727 | 0.87 | LMNA (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL179025 | 0.86 | HPGD (0.84) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5820481 | 0.85 | HPGD (0.68) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5820488 | 0.85 | HPGD (0.68) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1709310 | 0.85 | HPGD (0.73) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL179085 | 0.84 | RAB9A (0.76) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL108701 | 0.84 | KMT2A (0.73) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6952390 | 0.83 | HSD17B10 (0.66) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2937877 | 0.83 | SMN1; SMN2 (0.70) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698170-A1 | GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS | Eberhard-Karls-Universität Tübingen (DE) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024218333-A1 | GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT (DE) | 2024-10-24 | — | — | WO | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| WO-2021127459-A1 | GPR139 RECEPTOR MODULATORS | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1553092-B1 | ARALKYL FORMYL-ALKYL PIPERAZINE DERIVATIVES AND THEIR USES AS CEREBRAL NERVE PROTECTIVE AGENT | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-11-04 | — | — | EP | disclosed |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | COUSINS RUSSELL D | 2008-11-27 | — | — | US | disclosed |
| US-7326710-B2 | Aralkyl formyl-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2008-02-05 | — | — | US | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
| US-20050153981-A1 | Aralkyl formly-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-07-14 | — | — | US | disclosed |
| EP-1553092-A1 | ARALKYL FORMYL-ALKYL PIPERAZINE DERIVATIVES AND THEIR USES AS CEREBRAL NERVE PROTECTIVE AGENT | Shanghai Institute of Pharmaceutical Industry (CN) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | HPGD 571/4885HSD17B10 605/4885NPC1 3827/4885 |
| US-20050153981-A1 | Aralkyl formly-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | GAP43, FABP7, AGK | HPGD 1186/4885HSD17B10 3770/4885NPC1 2872/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | HPGD 3815/4885HSD17B10 2792/4885NPC1 37/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | HPGD 4624/4885HSD17B10 3600/4885NPC1 2966/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | HPGD 3815/4885HSD17B10 2792/4885NPC1 37/4885 |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | NOS2, NOS1, NOS3 | HPGD 72/4885HSD17B10 4280/4885NPC1 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.